PTN · Palatin Technologies Inc
$10.03
-0.44 (-4.20%)
At close · Aug 27
Going-concern doubt
— cleared May 13, 2026
The latest filing states the doubt was alleviated.
“While the Company has raised funding in the past, the ability to raise funding in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future funding in their assessment of the Company's ability to meet its obligations for the next year. Based on the Company's current operating and development plans, including the ability to reduce or delay operating expenses that are within management's control, the Company expects that its existing cash and cash equivalents as of the date of this filing will be sufficient to enable it to fund operations through the next twelve months following the issuance of the financial statements.”View the 10-Q filed May 13, 2026
Market Cap
$18.63M
Shares
1.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.47
Open$10.60
Day$9.26–10.93
52W close$5.75–28.00
Avg vol 30d22K
Short int350K · 19.6% float · 11.3d
Short vol77%
Last earningsMay 13, 2026
DataAug 2025–Aug 2026
Filing10-Q · May 13
Raw chart and full-history price indicators begin at the captured split on Aug 12, 2025; bars on opposite sides are not compared.
Up next
Next earnings call
Sep 28, 2026
Est · unconfirmed
· in 4 wks
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−35%
below
Price vs 50-day avg
+10%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
21%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+30%
trailing
6-month return
−53%
trailing
YTD return
−32%
this year
Relative strength
−65%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $16 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.64% of float · ▲ +17.8% MoM · 11.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — mid 3-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+68%
Y/Y
Free cash flow
$-21.3M
Balance sheet
$2.2M
net cash
Quant / Vol
risk profile
Volatility
134%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
9.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−35%
Bearish
Price vs 50-day avg
+10%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
21%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $10 › 200d $16 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.64% of float · ▲ +17.8% MoM · 11.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6
Now $10 · 21%
Range high $28
vs 200-day avg -35%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTN
this stock
Palatin Technologies Inc
|
$18.63M | -31.9% | -100.0% | — | 19.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Aug 12, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTN | +2.9% | +29.6% | -52.8% | +36.0% | -31.9% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +3.2% | +24.6% | -65.3% | +33.4% | -44.3% |